- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A randomized, double-blind, placebo-controlled, multicenter trial assessing the reduction of the rate of lipoprotein apheresis after treatment with pelacarsen (TQJ230) compared to placebo in patients with hyperlipoproteinemia(a) and established cardiovascular disease undergoing weekly lipoprotein apheresis in Germany
This study looks at a new medicine called pelacarsen (TQJ230) for people with high levels of a certain type of fat in their blood, called Lp(a). These people are already having a special treatment called lipoprotein apheresis. The study wants to see if pelacarsen can help reduce how often they need this treatment.
For: ApheresisGermany - Active not recruitingPHASE3
Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD
This study is looking into a new medication called Pelacarsen. It aims to see if this medicine can help people with heart disease who have high levels of a specific type of 'bad' cholesterol (Lipoprotein(a)) reduce their risk of future heart problems.
For: Cardiovascular Disease and Lipoprotein(a)United States · Argentina · Australia